

Drug Monograph

Drug/Drug **Dexmedetomidine Hydrochloride solution for injection /**
 Class: **Sedatives**
 Prepared for: MO HealthNet
 Prepared by: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Dexmedetomidine Hydrochloride Injection is now available in a flexible plastic infusion bag in strengths containing 200 mcg/50 ml single-dose or 400 mcg/100 ml single-dose.

Manufacturer: Manufactured for: WG Critical Care, LLC., Paramus, NJ 07652

Indications: Dexmedetomidine Hydrochloride Injection is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. It is also indicated for sedation of non-intubated patients prior to and/or during surgical and other procedures.

Costs: \$36 per 50 ml bag of 200 mcg and \$53 per 100 ml bag of 400 mcg of Dexmedetomidine Hydrochloride. Wholesale Acquisition Cost

Summary of Findings: MO HealthNet Division recommends Open Access status for this product.

Status Recommendation: Prior Authorization (PA) Required Open Access
 Fiscal Edit PDL

Type of PA Criteria: Increased Risk of ADE Preferred
 Appropriate Indications No PA Required

Prepared by: Luke Boehmer PharmD
 Date: February 26, 2019